

Candida auris

Interim Recommendations for Healthcare Outbreak Response

A. Background

Candida auris is an emerging multidrug resistant yeast that can cause invasive infections associated with high mortality. *C. auris* can persist on surfaces and medical equipment, spread between patients, and lead to outbreaks in healthcare settings. In addition, *C. auris* can be misidentified as other yeasts (most often as *Candida haemulonii*) by commonly available identification methods.

Nearly all of the cases identified in the United States occurred after mid-2015, primarily in New York City, New Jersey, and Chicago. Approximately half of U.S. clinical cases have been bloodstream infections; the other half involved non-sterile sites such as urine, respiratory tract, and wounds. *C. auris* can also colonize the skin and nares, and other body sites. Patients can be colonized with *C. auris* for long periods of time, even after successful treatment of infection. Although patients colonized with *C. auris* in non-sterile sites may not need medical treatment, they can be a source of transmission to others.

Risk of infection or colonization with *C. auris* is greatest among persons: (a) with extensive exposure to healthcare facilities, especially long-term care facilities with ventilator units; (b) infected or colonized with another multidrug-resistant organism, especially carbapenemase-producing organisms (CPOs); (c) with central venous catheters; (d) tracheostomy or gastrostomy tubes. U.S. healthcare personnel and public health authorities should also remain vigilant for *C. auris* in persons who were hospitalized in other countries where extensive *C. auris* transmission has been reported (see the CDC *C. auris* website for details)¹

B. Outbreak Detection and Reporting

1. Proposed Investigation/Reporting Thresholds and Outbreak Definition for *Candida auris*

The thresholds and definitions below are intended to serve as a guideline and are based on expert opinion except as noted otherwise. State and local public health authorities may have their own outbreak definitions and requirements for reporting. Since this is a new and emerging pathogen, healthcare facilities should have a low threshold for investigation to identify any potential cases and report to public health.

Table or Translated form of Table

	ALL HEALTHCARE SETTINGS
Threshold for facility to start investigation	1 <i>Candida auris</i> isolate from any specimen source ¹ OR 1 suspected <i>C. auris</i> isolate, ² including <i>Candida haemulonii</i> , from any specimen source ¹ , identified by a yeast identification method not equipped to detect <i>C. auris</i> ³
Threshold for reporting to public health	1 <i>Candida auris</i> isolate from any specimen source ¹ OR 1 Suspected <i>C. auris</i> isolate, ² including <i>Candida haemulonii</i> , from any specimen source ¹ or any commonly misidentified organism based on yeast identification system, ³
Outbreak definition	≥2 cases of confirmed or suspected <i>Candida auris</i> from clinical or screening cultures with an epidemiologic link ^{1, 2, 4}

¹ Any specimen, including those obtained for clinical care, screening purposes, or point prevalence surveys.

² While confirmatory test results are pending, implement appropriate infection prevention and control measures for *C. auris* (see section 3 for detailed guidance).² If isolates are not confirmed as *C. auris*, no additional investigation is warranted, unless another type of outbreak is suspected.

³ *C. auris* can be misidentified as different yeasts when using phenotypic methods for yeast identification (see 2.4 for more details).

⁴ An epidemiologic link includes but is not limited to the following examples: residing on same unit (or within same facility if facility is smaller), transferred from the same outside facility, facility staff in common, and/or exposed to common medical equipment.

2. Points for Consideration

- 2.1. All *Candida* isolates from sterile sites should be worked up to the species level to guide treatment.
- 2.2. Many clinical labs do not routinely speciate candida from non-sterile sites.
 - 2.2.1 Facilities should be aware of practices in their laboratory with regards to what methodology is used for *Candida* species identification and its ability to accurately detect *C. auris*, and what types of specimens are routinely identified to species level.
- 2.3. Consider determining the species of *Candida* isolates from non-sterile/non-invasive sites in the following situations:³
 - 2.1.1. It is clinically indicated in the care of the patient (e.g. suspected infection or treatment failure). The patient is colonized or infected with another multi-drug resistant organism (MDRO), especially carbapenemase-producing organisms (CPOs)
 - 2.1.2. There is an epidemiological link to a patient known to have *C. auris*
 - 2.1.3. The patient has had an overnight healthcare stay in the prior year in a country with known *C. auris* transmission⁴
 - 2.1.4. There is an increase in unspciated *Candida* isolates (from any specimen source) within a unit
- 2.4. Communicate directly with the laboratory when there is a high level of suspicion for *C. auris*

- 2.4.1. *C. auris* should be suspected when certain *Candida* spp. are identified by specific yeast identification methods or if the species of *Candida* cannot be determined after species identification is attempted.
- 2.4.2. The Centers for Disease Control and Prevention (CDC) provides details about *C. auris* identification and when to suspect *C. auris*.⁵ Healthcare facilities should contact their local or state public health department to facilitate confirmatory laboratory testing. Health departments should contact their regional Antibiotic Resistance Lab Network (ARLN) and CDC for confirmatory laboratory testing.

C. Investigation and Control

The following sections outline important actions and considerations in conducting a *C. auris* investigation in an Acute or Long-Term Care Facility (please see the primary references for additional details). Some of these actions can be conducted by the facility, while others may require assistance from the health department. Collaboration between the facility and public health helps ensure a successful investigation. Public health should support the facility by providing guidance and resources. The health department may be able to provide assistance with infection control assessment, medical record review, laboratory testing, data analysis, and other activities as appropriate for the investigation. This will depend on the circumstances of the potential outbreak as well as the resources of the facility and the health department. The need for an on-site visit to the facility should be determined based on the number of the cases, patient population, severity of illness, and level of assistance required.

Components of an investigation and response to *C. auris* generally include those listed in CDC's Interim Guidance for a Public Health Response to Contain Novel or Targeted MDRO and additional information outlined on the CDC *C. auris* infection prevention and control website.⁶ Typically, these investigations will be guided by state/local public health departments, with active consultation with CDC. This is especially true for long term care facilities.

1. Initial Investigation/Case Review

- 1.1. When conducting health care facility investigations of *C. auris*, engage both infection prevention/healthcare epidemiology and clinical microbiology laboratory staff.
- 1.2. Identify recent health care encounters, including stays at other health care facilities during the three months preceding *C. auris* identification. A review encompassing a longer period should be considered if information is available regarding the likely time of *C. auris* acquisition, e.g., healthcare exposure outside the United States in a country with known *C. auris* transmission greater than three months prior to identification.⁷
 - 1.2.1. Notify and coordinate with state and local public health departments to alert and conduct investigations at other facilities, as necessary.
- 1.3. Confirm *C. auris* identification, if necessary; conduct enhanced microbiologic surveillance for *C. auris*.
- 1.4. If ≥ 1 case of *C. auris* is identified at a facility, the facility should perform species identification on all *Candida* isolates identified from any body site on affected unit(s) for a limited time (e.g., 90 days) until there is no evidence of ongoing transmission.⁸ Include non-sterile sites such as urine and respiratory tract where species of *Candida* may not be routinely determined.

2. Contact Screening

- 2.1. Because of high level of transmissibility of *C. auris*, in any healthcare setting, consider conducting a point prevalence survey (PPS) of all patients on the unit with the *C. auris* patient.
 - 2.1.1. In a long-term care facility, consider conducting a PPS even if the index patient was discharged up to three months ago.
 - 2.1.2. If multiple previous healthcare facility stays are identified, consider prioritizing long-term acute care hospitals and high acuity LTCFs that provide ventilator/tracheostomy care in consultation with public health.
- 2.2. At a minimum, current and past roommates dating back at least one month from the date of *C. auris* identification should be screened.⁹
- 2.3. Coordinate with CDC and your regional public health laboratory to perform *C. auris* screening of patients. Screening is typically performed by obtaining a composite swab of the bilateral axillae and groin.¹⁰ Patients can also be colonized in the nares and other sites; in consultation with public health, consider screening additional sites in high-risk settings or when transmission is suspected.

3. Patient Placement and Cohorting

- 3.1. Cohort patients with *C. auris* colonization or infection in the same area of the facility.
 - 3.1.1. Minimize the number of staff who care for these patients.
- 3.2. Place patients with *C. auris* colonization or infection in a single room.
- 3.3. If necessary, multiple patients with *C. auris* may be placed together in multi-occupancy rooms. Roommate considerations include:
 - 3.3.1. Patients co-colonized with *C. auris* and carbapenemase-producing organisms (CPO) may be placed together based on the CPO resistance mechanism. Avoid placing co-colonized patients with different mechanisms of CPO resistance (e.g. KPC with VIM).
 - 3.3.2. Patients without evidence of *C. auris* colonization (even if they have not been screened or screening results are pending) may be placed together with *C. auris* screen-negative patients.

4. Infection Control Measures

- 4.1. Implement Contact Precautions for patients colonized or infected with *C. auris*.
 - 4.1.1. In multi-occupancy rooms, ensure healthcare workers change gloves and gowns and perform hand hygiene between patients.
- 4.2. Emphasize rigorous adherence to hand hygiene; alcohol-based hand rub is acceptable unless hands are visibly soiled, in which case soap and water are indicated.
- 4.3. Dedicate patient care equipment such as blood pressure cuffs, thermometers, blood glucose meters, and stethoscopes; use single use disposable items when possible.
- 4.4. Audit infection control practices on affected unit(s), including hand hygiene, contact precautions (e.g., donning and doffing of gowns and gloves), and environmental cleaning^{11 12 13}. Provide feedback, education, and additional audits to raise compliance, as needed.¹⁴
- 4.5. Public health may modify this guidance as additional information and recommendations become available ([Enhanced Barrier Precautions](#)).

5. Environmental Cleaning and Disinfection

- 5.1. Ensure daily environmental cleaning and disinfection is performed using an Environmental Protection Agency (EPA)-registered hospital-grade disinfectant effective against *C. difficile* (List K); for additional details and alternatives, refer to [the CDC *C. auris* infection prevention and control website](#).
- 5.2. High touch surfaces require more frequent cleaning and disinfecting.
- 5.3. Although dedicated patient equipment should be used whenever possible (see 4.3), equipment and devices that are shared must be cleaned and disinfected between uses (e.g., thermometers, blood glucose meters, vital signs machines, and equipment such as imaging that might be shared between multiple facilities).¹⁵
- 5.4. Delegate cleaning and disinfection of all environmental surfaces and equipment to designated personnel and consider using standardized checklists to ensure all surfaces and equipment are cleaned.
- 5.5. Audit cleaning procedures on affected units. Consider the use of marking and/or direct observations to ensure cleaning effectiveness. Provide feedback to environmental services (EVS) staff.
- 5.6. In facilities with multi-occupancy rooms, ensure that each bed space is cleaned and disinfected as a different room.
- 5.7. Ensure manufacturer's instructions for use pertaining to cleaning and reprocessing of medical equipment are followed.
- 5.8. Ensure disinfectant product is used according to instructions for use and for the recommended contact time.
- 5.9. Include environmental services (EVS) personnel as integral part of infection control team, for example, include EVS in environment of care rounds.

6. Communication

- 6.1. Health care facilities should consider engaging their public affairs/communications staff, especially when conducting ward/unit or facility-wide point prevalence survey(s).
- 6.2. Health care facilities and public health agencies should be prepared to address questions from patients, family members and healthcare workers regarding the risk of *C. auris* colonization and infection and whether healthcare workers and household contacts should be screened. Information for patients and family members is available from the CDC.¹⁶
- 6.3. Develop or adapt patient and staff communication tools to explain *C. auris* screening, especially if conducting ward/unit or facility-wide point prevalence survey(s). CDC has developed *Frequently asked Questions about Screening for Candida auris* that can guide communication.¹⁷
- 6.4. Decisions to transfer the patient from one level of care to another should be based on clinical criteria and the ability of the accepting facility to provide care, and not on the presence or absence of *C. auris* infection or colonization.¹⁸
- 6.5. When patients are transferred to other healthcare facilities, ensure receiving facilities receive notification of the patient's *C. auris* infection or colonization, and understand the necessary infection control precautions.¹⁹

7. Monitoring and Follow-up

If multiple cases of *C. auris* infection or colonization are identified at a health care facility, additional considerations include:

- 7.1. Serial point prevalence surveys among patients residing on wards or units where *C. auris* transmission is suspected.²⁰ Conduct surveys every 2-4 weeks until at least two sequential point prevalence surveys do not identify new cases.
- 7.2. Repeated onsite infection control assessment(s) to reinforce adherence to infection control measures.
- 7.3. Additional case finding around newly identified cases.
- 7.4. Regional notification and surveillance in coordination with local/state public health department(s).²¹

Content with no reference specified is based on CORHA subject matter expert opinion.

Disclaimer: The positions and views expressed in this guidance do not necessarily represent the official positions of CORHA's member organizations.

D. References

- ¹ Centers for Disease Control and Prevention. Fungal Diseases. Tracking *Candida auris*. Available at: <https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html> Accessed June 22, 2018.
- ² Centers for Disease Control and Prevention. Fungal Diseases. Healthcare Professionals. Recommendations for Infection Prevention and Control for *Candida auris*. Available at: <https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html> Accessed June 22, 2018.
- ³ Centers for Disease Control and Prevention. Fungal Diseases. Healthcare Professionals. *Candida auris* Clinical Update – September 2017. Available at: <https://www.cdc.gov/fungal/candida-auris/c-auris-alert-09-17.html> Accessed June 22, 2018.
- ⁴ Centers for Disease Control and Prevention. Fungal Diseases. Tracking *Candida auris*. Available at: <https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html> Accessed June 22, 2018.
- ⁵ Centers for Disease Control and Prevention. Fungal Disease Healthcare Professionals. Recommendations for Identification of *Candida auris*. Available at: <https://www.cdc.gov/fungal/candida-auris/recommendations.html> Accessed: June 22, 2018.
- ⁶ Centers for Disease Control and Prevention. Interim Guidance for a Public Health Response to Contain Novel or Targeted Multidrug-resistant Organisms (MDRO). Available at: <https://www.cdc.gov/hai/outbreaks/docs/Health-Response-Contain-MDRO.pdf>. Accessed August 21, 2018.
- ⁷ Ibid.
- ⁸ Tsay S; Kallen A; Jackson BR; Chiller TM; Vallabhaneni S. Approach to the investigation and Management of Patients with *Candida auris*, an Emerging Multidrug-resistant Yeast. Clin Infect Dis. 2018 January 06; 66(2): 306–311. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798232/pdf/nihms937613.pdf> Accessed August 21, 2018.
- ⁹ Ibid.
- ¹⁰ Ibid.
- ¹¹ Centers for Disease Control and Prevention. Acute Care Facility Multidrug-resistant Organisms Control Activity Assessment Tool. Available at: https://www.cdc.gov/HAI/pdfs/prevent/MDRO-Facility-Assessment_7_28.pdf Accessed August 21, 2018.
- ¹² Centers for Disease Control and Prevention. Infection Control. Tools for Healthcare Settings. Available at: <https://www.cdc.gov/infectioncontrol/tools/index.html> Accessed August 21, 2018.
- ¹³ California Department of Public Health. Healthcare-Associated Infections (HAI) Program. Monitoring Adherence to Health Care Practices that Prevent Infection. Available at: <https://www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/MonitoringAdherenceToHCPacticesThatPreventInfection.aspx> Accessed August 21, 2018.
- ¹⁴ Centers for Disease Control and Prevention. Interim Guidance for a Public Health Response to Contain Novel or Targeted Multidrug-resistant Organisms (MDRO). Available at: <https://www.cdc.gov/hai/outbreaks/docs/Health-Response-Contain-MDRO.pdf>. Accessed August 21, 2018.
- ¹⁵ Centers for Disease Control and Prevention. Fungal Diseases. Healthcare Professionals. Recommendations for Infection Prevention and Control for *Candida auris*. Available at: <https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html> Accessed June 22, 2018.
- ¹⁶ Centers for Disease Control and Prevention. *Candida auris*. *Candida auris* Information for Patients and Family Members. Available at: <https://www.cdc.gov/fungal/candida-auris/patients-qa.html> Accessed August 21, 2018.
- ¹⁷ Centers for Disease Control and Prevention. *Candida auris*. Frequently asked Questions about Screening for *Candida auris*. Available at: <https://www.cdc.gov/fungal/candida-auris/c-auris-screening-info.html> Accessed August 21, 2018.
- ¹⁸ Ibid.
- ¹⁹ Centers for Disease Control and Prevention. Fungal Diseases. Healthcare Professionals. Recommendations for Infection Prevention and Control for *Candida auris*. Available at: <https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html> Accessed June 22, 2018.
- ²⁰ Ibid.
- ²¹ Ibid.